Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
G1XCGD in Patients With X-Linked Chronic Granulomatous Disease
NCT07113743Phase 2Enrolling by invitation
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Sep 2025
- Primary completion
- Sep 2028
- Countries
- 1
01
Overview
A Phase 2 trial of G1XCGD in X-linked chronic granulomatous disease (X-CGD), sponsored by National Institute of Allergy and Infectious Diseases. Started Sep 2025; status: enrolling by invitation.
02
Drugs
G1XCGD
03
Conditions
X-linked chronic granulomatous disease (X-CGD)
Beyond the preview
Go deeper on NCT07113743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07113743.